474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

• Rachel Sanborn,
• Stephen Ansell,
• Vincent Ribrag,
• Diwakar Davar,
• Ecaterina Dumbrava,
• Elena Garralda,
• Carmen Belli,
• Clementine Sarkozy,
• Honey Kumar Oberoi,
• Amitkumar Mehta,
• Jasmine Zain,
• Alex Herrera,
• Andres Forero-Torres

Affiliations

Rachel Sanborn

Aff2 grid.415337.7Robert W. Franz Cancer Research Center, Earle A. Chiles Research InstituteProvidence Cancer Center Portland OR USA

Stephen Ansell

Aff1 grid.66875.3a000000040459167XMayo Clinic Rochester MN USA

Vincent Ribrag

Aff25 grid.14925.3b0000000122849388Institut Gustave Roussy Villejuif Ile-de-France France

Diwakar Davar

1University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Ecaterina Dumbrava

1MD Anderson Cancer Center, Houston, TX, USA

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Carmen Belli

Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

Clementine Sarkozy

2Gustave-Roussy Institute, Villejuif, France

Honey Kumar Oberoi

3Vall d’Hebron University Hospital, Barcelona, Spain

Amitkumar Mehta

4Birmingham Comprehensive Cancer Center, Birmingham, AL, USA

Jasmine Zain

7City of Hope Medical Center, Duarte, CA, USA

Alex Herrera

7City of Hope Medical Center, Duarte, CA, USA

Andres Forero-Torres

10Seagen Inc, Seattle, WA, USA